The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics

Journal of Proteomics

Volumn 76, Issue , 2012, Pages 102-115

  Luna Coronell, Johana A ^a   Syed, Parvez ^a   Sergelen, Khulan ^a   Gyurján, István ^a   Weinhäusel, Andreas ^a  

^a AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

Author keywords

Autoantibody tumour biomarkers; Phage display; Protein microarrays; SEREX; SERPA; Tumour associated antigens

Indexed keywords

BETA TUBULIN; BIOLOGICAL MARKER; BRCA2 PROTEIN; CARCINOEMBRYONIC ANTIGEN; CHAPERONIN 60; CYCLIN B1; DIFFERENTIATION ANTIGEN; HAPTOGLOBIN; HEAT SHOCK PROTEIN 70; LIPOCORTIN 1; LIPOCORTIN 2; MUCIN 1; MYC PROTEIN; NY ESO 1 ANTIGEN; PEROXIREDOXIN 2; PHOSPHOGLYCERATE MUTASE; PROHIBITIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C; PROTEIN P16; PROTEIN P53; PROTEIN P62; PROTEIN P90; SOMATOMEDIN BINDING PROTEIN 2; SURVIVIN; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX3; TUMOR ANTIGEN; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AREA UNDER THE CURVE; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CROSS REACTION; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; FAMILY HISTORY; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; LUNG CANCER; MAMMOGRAPHY; MEDICAL RESEARCH; MINIMALLY INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD TEST; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGICAL ANALYSIS OF RECOMBINANT CDNA EXPRESSION LIBRARY; SEROLOGICAL POTEOMICS ANALYSIS; TUMOR GENE;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869883657     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.022     Document Type: Article

References (157)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Lubin R., Zalcman G., Bouchet L., Trédanel J., Legros Y., Cazals D., et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995, 1:701-702.
3. Trivers G.E., De Benedetti V.M., Cawley H.L., Caron G., Harrington A.M., Bennett W.P., et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996, 2:1767-1775.
4. Abendstein B., Marth C., Muller-Holzner E., Widschwendter M., Daxenbichler G., Zeimet A.G. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 2000, 88:1432-1437.
5. Anderson K.S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4:1123-1133.
6. Casiano C.A., Mediavilla-Varela M., Tan E.M. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 2006, 5:1745-1759.
7. Sanchez-Carbayo M. Antibody arrays: technical considerations and clinical applications in cancer. Clin Chem 2006, 52:1651-1659.
8. Tomkiel J.E., Alansari H., Tang N., Virgin J.B., Yang X., VandeVord P., et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res 2002, 8:752-758.
9. Frenkel K., Karkoszka J., Glassman T., Dubin N., Toniolo P., Taioli E., et al. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev 1998, 7:49-57.
10. Piura E., Piura B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol 2011, 2011:982425.
11. Chapman C., Murray A., Chakrabarti J., Thorpe A., Woolston C., Sahin U., et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007, 18:868-873.
12. Peng G., Hakim M., Broza Y.Y., Billan S., Abdah-Bortnyak R., Kuten A., et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer 2010, 103:542-551.
13. Bermejo-Pérez M.J., Márquez-Calderón S., Llanos-Méndez A. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. Br J Radiol 2008, 81:172-179.
14. Brooks J., Cairns P., Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control 2009, 20:1539-1550.
15. Egger G., Wielscher M., Pulverer W., Kriegner A., Weinhäusel A. DNA methylation testing and marker validation using PCR: diagnostic applications. Expert Rev Mol Diagn 2012, 12:75-92.
16. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 2007, 7:531-543.
17. Nagler H.M., Gerber E.W., Homel P., Wagner J.R., Norton J., Lebovitch S., et al. Digital rectal examination is barrier to population-based prostate cancer screening. Urology 2005, 65:1137-1140.
18. Lee A.G., Choi Y.H., Cho S.Y., Cho I.R. A prospective study of reducing unnecessary prostate biopsy in patients with high serum prostate-specific antigen with consideration of prostatic inflammation. Korean J Urol 2012, 53:50-53.
19. Hoffman R.M., Gilliland F.D., Adams-Cameron M., Hunt W.C., Key C.R. Prostate-specific antigen testing accuracy in lcommunity practice. BMC Fam Pract 2002, 3:19.
20. Roobol M.J., van Vugt H.A., Loeb S., Zhu X., Bul M., Bangma C.H., et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012, 61:577-583.
21. Ramos C.G., Valdevenito R., Vergara I., Anabalon P., Sanchez C., Fulla J. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Urol Oncol 2012, [Epub ahead of print] http://dx.doi.org/10.1016/j.urolonc.2012.05.002.
22. Roobol M.J., Schröder F.H., van Leeuwen P., Wolters T., van den Bergh R.C., van Leenders G.J., et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010, 58:475-481.
23. Prensner J.R., Rubin M.A., Wei J.T., Chinnaiyan A.M. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012, 4:127rv3.
24. Reddy C., Chilla D., Boltax J. Lung cancer screening: a review of available data and current guidelines. Hosp Pract (Minneap) 2011, 39:107-112.
25. Leidinger P., Keller A., Heisel S., Ludwig N., Rheinheimer S., Klein V., et al. Identification of lung cancer with high sensitivity and specificity by blood testing. Respir Res 2010, 11:18.
26. Dietrich D., Kneip C., Raji O., Liloglou T., Seegebarth A., Schlegel T., et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 2012, 40:825-832.
27. Liu W., Wang P., Li Z., Xu W., Dai L., Wang K., et al. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol 2009, 69:57-63.
28. Levin B., Brooks D., Smith R.A., Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 2003, 53:44-55.
29. Allison J.E., Tekawa I.S., Ransom L.J., Adrain A.L. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996, 334:155-159.
30. Gangadharan B., Antrobus R., Dwek R.A., Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007, 53:1792-1799.
31. Pan S., Shi M., Jin J., Albin R.L., Lieberman A., Gearing M., et al. Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. Mol Cell Proteomics 2007, 6:1818-1823.
32. Meyer H.E., Stuhler K. High-performance proteomics as a tool in biomarker discovery. Proteomics 2007, 7(Suppl. 1):18-26.
33. Clarke C.H., Buckley J.A., Fung E.T. SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med 2005, 43:1314-1320.
34. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004, 3:367-378.
35. Mathelin C., Cromer A., Wendling C., Tomasetto C., Rio M.C. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 2006, 96:83-90.
36. Borrebaeck C.A., Wingren C. High-throughput proteomics using antibody microarrays: an update. Expert Rev Mol Diagn 2007, 7:673-686.
37. Hu S., Li Y., Liu G., Song Q., Wang L., Han Y., et al. A protein chip approach for high-throughput antigen identification and characterization. Proteomics 2007, 7:2151-2161.
38. Li Y., Lee H.J., Corn R.M. Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. Anal Chem 2007, 79:1082-1088.
39. Diesinger I., Bauer C., Brass N., Schaefers H.J., Comtesse N., Sybrecht G., et al. Toward a more complete recognition of immunoreactive antigens in squamous cell lung carcinoma. Int J Cancer 2002, 102:372-378.
40. Krackhardt A.M., Witzens M., Harig S., Hodi F.S., Zauls A.J., Chessia M., et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002, 100:2123-2131.
41. Tureci O., Usener D., Schneider S., Sahin U. Identification of tumor-associated autoantigens with SEREX. Methods Mol Med 2005, 109:137-154.
42. Wang Y., Han K.J., Pang X.W., Vaughan H.A., Qu W., Dong X.Y., et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 2002, 169:1102-1109.
43. Qian F., Odunsi K., Blatt L.M., Scanlan M.J., Mannan M., Shah N., et al. Tumor associated antigen recognition by autologous serum in patients with breast cancer. Int J Mol Med 2005, 15:137-144.
44. Fosså A., Siebert R., Aasheim H.C., Maelandsmo G.M., Berner A., Fosså S.D., et al. Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer. Br J Cancer 2000, 83:743-749.
45. Stone B., Schummer M., Paley P.J., Thompson L., Stewart J., Ford M., et al. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 2003, 104:73-84.
46. Devitt G., Meyer C., Wiedemann N., Eichmüller S., Kopp-Schneider A., Haferkamp A., et al. Serological analysis of human renal cell carcinoma. Int J Cancer 2006, 118:2210-2219.
47. Vaughan H.A., St C.F., Scanlan M.J., Chen Y.T., Maraskovsky E., Sizeland A., et al. The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning. Cancer Immun 2004, 4:5.
48. Shimada H., Nakashima K., Ochiai T., Nabeya Y., Takiguchi M., Nomura F., et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol 2005, 26:77-86.
49. Liggins A.P., Guinn B.A., Banham A.H. Identification of lymphoma-associated antigens using SEREX. Methods Mol Med 2005, 115:109-128.
50. Umano Y., Tsunoda T., Tanaka H., Matsuda K., Yamaue H., Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001, 84:1052-1057.
51. Würtzen P.A., Pedersen L.Ø., Poulsen H.S., Claesson M.H. Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line. Int J Cancer 2001, 93:855-861.
52. Azuma K., Shichijo S., Maeda Y., Nakatsura T., Nonaka Y., Fujii T., et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res 2003, 63:854-858.
53. Somasundaram R., Swoboda R., Caputo L., Otvos L., Weber B., Volpe P., et al. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006, 66:3287-3293.
54. Backes C., Ludwig N., Leidinger P., Harz C., Hoffmann J., Keller A., et al. Immunogenicity of autoantigens. BMC Genomics 2011, 12:340.
55. Baurain J.F., Colau D., van Baren N., Landry C., Martelange V., Vikkula M., et al. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol 2000, 164:6057-6066.
56. Hall J.C., Casciola-Rosen L., Rosen A. Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am 2004, 30:455-471. [vii].
57. Pollard K.M., Lee D.K., Casiano C.A., Bluthner M., Johnston M.M., Tan E.M. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J Immunol 1997, 158:3521-3528.
58. Utz P.J., Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 1998, 41:1152-1160.
59. Rosen A., Casciola-Rosen L., Wigley F. Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 1997, 9:538-543.
60. Wu X., Molinaro C., Johnson N., Casiano C.A. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum 2001, 44:2642-2652.
61. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222:328-340.
62. Zhang J.Y. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detect Prev 2004, 28:114-118.
63. Lu H., Goodell V., Disis M.L. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008, 7:1388-1394.
64. Zhong L., Ge K., Zu J.C., Zhao L.H., Shen W.K., Wang J.F., et al. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res 2008, 10:R40.
65. Tschernatsch M., Gross O., Kneifel N., Kaps M., Blaes F. SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev 2009, 8:549-551.
66. Titulaer M.J., Klooster R., Potman M., Sabater L., Graus F., Hegeman I.M., et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009, 27:4260-4267.
67. Davis T.M., Mehta Z., Mackay I.R., Cull C.A., Bruce D.G., Fida S., et al. Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes. Diabet Med 2003, 20:198-204.
68. Koziol J.A., Zhang J.Y., Casiano C.A., Peng X.X., Shi F.D., Feng A.C., et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003, 9:5120-5126.
69. Babel I., Barderas R., Díaz-Uriarte R., Martínez-Torrecuadrada J.L., Sánchez-Carbayo M., Casal J.I. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 2009, 8:2382-2395.
70. Looi K., Megliorino R., Shi F.D., Peng X.X., Chen Y., Zhang J.Y. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 2006, 16:1105-1110.
71. Desmetz C., Bascoul-Mollevi C., Rochaix P., Lamy P.J., Kramar A., Rouanet P., et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009, 15:4733-4741.
72. Hamrita B., Chahed K., Kabbage M., Guillier C.L., Trimeche M., Chaïeb A., et al. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). Clin Chim Acta 2008, 393:95-102.
73. Zhang J.Y., Casiano C.A., Peng X.X., Koziol J.A., Chan E.K., Tan E.M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12:136-143.
74. Xie C., Kim H.J., Haw J.G., Kalbasi A., Gardner B.K., Li G., et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med 2011, 9:43.
75. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353:1224-1235.
76. Massoner P., Lueking A., Goehler H., Höpfner A., Kowald A., Kugler K.G., et al. Serum-autoantibodies for discovery of prostate cancer specific biomarkers. Prostate 2012, 72:427-436.
77. Sabater L., Titulaer M., Saiz A., Verschuuren J., Güre A.O., Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008, 70:924-928.
78. Wirtz P.W., Lang B., Graus F., van den Maagdenberg A.M., Saiz A., de Koning Gans P.A., et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005, 164:161-165.
79. Wu L., Chang W., Zhao J., Yu Y., Tan X., Su T., et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res 2010, 16:3760-3768.
80. Chapman C.J., Murray A., McElveen J.E., Sahin U., Luxemburger U., Türeci O., et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63:228-233.
81. Farlow E.C., Patel K., Basu S., Lee B.S., Kim A.W., Coon J.S., et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010, 16:3452-3462.
82. Kijanka G., Hector S., Kay E.W., Murray F., Cummins R., Murphy D., et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 2010, 59:69-78.
83. Carpelan-Holmstrom M., Haglund C., Lundin J., Jarvinen H., Roberts P. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer 1996, 32A:1156-1161.
84. Ran Y., Hu H., Zhou Z., Yu L., Sun L., Pan J., et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 2008, 14:2696-2700.
85. Chan C.C., Fan C.W., Kuo Y.B., Chen Y.H., Chang P.Y., Chen K.T., et al. Multiple serological biomarkers for colorectal cancer detection. Int J Cancer 2010, 126:1683-1690.
86. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.
87. Danner S., Belasco J.G. T7 phage display: a novel genetic selection system for cloning RNA-binding proteins from cDNA libraries. Proc Natl Acad Sci U S A 2001, 98:12954-12959.
88. Tan H.T., Low J., Lim S.G., Chung M.C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009, 276:6880-6904.
89. Mersmann M., Meier D., Mersmann J., Helmsing S., Nilsson P., Gräslund S. Structural Genomics Consortium, Colwill K, Hust M, Dübel S. Towards proteome scale antibody selections using phage display. N Biotechnol 2010, 27:118-128.
90. Bradford T.J., Wang X., Chinnaiyan A.M. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006, 24:237-242.
91. Kelly K.A., Jones D.A. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia 2003, 5:437-444.
92. Somers V.A., Brandwijk R.J., Joosten B., Moerkerk P.T., Arends J.W., Menheere P., et al. A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J Immunol 2002, 169:2772-2780.
93. Zhong L., Coe S.P., Stromberg A.J., Khattar N.H., Jett J.R., Hirschowitz E.A. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006, 1:513-519.
94. Chatterjee M., Mohapatra S., Ionan A., Bawa G., Ali-Fehmi R., Wang X., et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006, 66:1181-1190.
95. Sahin U., Türeci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
96. Wang Y., Gu Q., Liu B., Zhu Z. Perspectives of SEREX-defined antigens in diagnosis and immunotherapy for gastric cancer. Cancer Biol Ther Sep 2004, 3(9):806-811.
97. Lee S.Y., Jeoung D. The reverse proteomics for identification of tumor antigens. J Microbiol Biotechnol 2007, 17:879-890.
98. Schmits R., Cochlovius B., Treitz G., Regitz E., Ketter R., Preuss K.D., et al. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int J Cancer 2002, 98:73-77.
99. Cheever M.A., Disis M.L., Bernhard H., Gralow J.R., Hand S.L., Huseby E.S., et al. Immunity to oncogenic proteins. Immunol Rev 1995, 145:33-59.
100. Türeci O., Sahin U., Vollmar E., Siemer S., Göttert E., Seitz G., et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci U S A 1998, 95:7608-7613.
101. Scanlan M.J., Chen Y.T., Williamson B., Gure A.O., Stockert E., Gordan J.D., et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998, 76:652-658.
102. Line A., Slucka Z., Stengrevics A., Silina K., Li G., Rees R.C. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother 2002, 51:574-582.
103. Jäger D., Stockert E., Güre A.O., Scanlan M.J., Karbach J., Jäger E., et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001, 61:2055-2061.
104. Jäger D., Stockert E., Scanlan M.J., Güre A.O., Jäger E., Knuth A., et al. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res 1999, 59:6197-6204.
105. Fosså A., Alsøe L., Crameri R., Funderud S., Gaudernack G., Smeland E.B. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004, 53:431-438.
106. Scanlan M.J., Welt S., Gordon C.M., Chen Y.T., Gure A.O., Stockert E., et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002, 62:4041-4047.
107. Scanlan M.J., Gout I., Gordon C.M., Williamson B., Stockert E., Gure A.O., et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun Mar 30 2001, 1:4.
108. Ishikawa T., Fujita T., Suzuki Y., Okabe S., Yuasa Y., Iwai T., et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 2003, 63:5564-5572.
109. Güre A.O., Altorki N.K., Stockert E., Scanlan M.J., Old L.J., Chen Y.T. Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res 1998, 58:1034-1041.
110. Güre A.O., Stockert E., Scanlan M.J., Keresztes R.S., Jäger D., Altorki N.K., et al. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 2000, 97:4198-4203.
111. Zhou Y., Toth M., Hamman M.S., Monahan S.J., Lodge P.A., Boynton A.L., et al. Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. Biochem Biophys Res Commun 2002, 290:830-838.
112. Ojika T., Imaizumi M., Abe T., Kato K. Immunochemical and immunohistochemical studies on three aldolase isozymes in human lung cancer. Cancer 1991, 67:2153-2158.
113. Asaka M., Kimura T., Meguro T., Kato M., Kudo M., Miyazaki T., et al. Alteration of aldolase isozymes in serum and tissues of patients with cancer and other diseases. J Clin Lab Anal 1994, 8:144-148.
114. Lichtenfels R., Kellner R., Atkins D., Bukur J., Ackermann A., Beck J., et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003, 1646:21-31.
115. Unwin R.D., Harnden P., Pappin D., Rahman D., Whelan P., Craven R.A., et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003, 3:45-55.
116. Klade C.S., Voss T., Krystek E., Ahorn H., Zatloukal K., Pummer K., et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001, 1:890-898.
117. Gunawardana C.G., Diamandis E.P. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 2007, 249:110-119.
118. Sato T., Saito H., Swensen J., Olifant A., Wood C., Danner D., et al. The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res 1992, 52:1643-1646.
119. Suzuki A., Iizuka A., Komiyama M., Takikawa M., Kume A., Tai S., et al. Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010, 7:17-23.
120. He Y., Wu Y., Mou Z., Li W., Zou L., Fu T., et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl 2007, 1:336-342.
121. Desmetz C., Mange A., Solassol J. Comparison of proteomic strategies to identify antibodies resulting from the humoral immune response to cancer. Med Sci (Paris) 2008, 24:1071-1076.
122. Balboni I., Chan S.M., Kattah M., Tenenbaum J.D., Butte A.J., Utz P.J. Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol 2006, 24:391-418.
123. Gygi S.P., Corthals G.L., Zhang Y., Rochon Y., Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000, 97:9390-9395.
124. Yalow R.S., Berson S.A. Assay of plasma insulin in human subjects by immunological methods. Nature 1959, 184(Suppl. 21):1648-1649.
125. Engvall E., Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971, 8:871-874.
126. Ekins R., Chu F., Biggart E. Multispot, multianalyte, immunoassay. Ann Biol Clin (Paris) 1990, 48:655-666.
127. Silzel J.W., Cercek B., Dodson C., Tsay T., Obremski R.J. Mass-sensing, multianalyte microarray immunoassay with imaging detection. Clin Chem 1998, 44:2036-2043.
128. Tomizaki K.Y., Usui K., Mihara H. Protein-detecting microarrays: current accomplishments and requirements. Chembiochem 2005, 6:782-799.
129. Huang R.P., Huang R., Fan Y., Lin Y. Simultaneous detection of multiple cytokines from conditioned media and patient's sera by an antibody-based protein array system. Anal Biochem 2001, 294:55-62.
130. Nam M.J., Madoz-Gurpide J., Wang H., Lescure P., Schmalbach C.E., Zhao R., et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003, 3:2108-2115.
131. Olle E.W., Messamore J., Deogracias M.P., McClintock S.D., Anderson T.D., Johnson K.J. Comparison of antibody array substrates and the use of glycerol to normalize spot morphology. Exp Mol Pathol 2005, 79:206-209.
132. Fici D.A., McCormick W., Brown D.W., Herrmann J.E., Kumar V., Awdeh Z.L. A protein multiplex microarray substrate with high sensitivity and specificity. J Immunol Methods 2010, 363:60-66.
133. Lee D.W., Kim H.J., Choi C.H., Shin J.H., Kim E.K. Development of a protein chip to measure PKCbeta activity. Appl Biochem Biotechnol 2011, 163:803-812.
134. Kang M., Trofin L., Mota M.O., Martin C.R. Protein capture in silica nanotube membrane 3-D microwell arrays. Anal Chem 2005, 77:6243-6249.
135. Guilleaume B., Buness A., Schmidt C., Klimek F., Moldenhauer G., Huber W., et al. Systematic comparison of surface coatings for protein microarrays. Proteomics 2005, 5:4705-4712.
136. Zubtsov D.A., Savvateeva E.N., Rubina A.Y., Pan'kov S.V., Konovalova E.V., Moiseeva O.V., et al. Comparison of surface and hydrogel-based protein microchips. Anal Biochem 2007, 368:205-213.
137. Tanaka H., Hanasaki M., Isojima T., Takeuchi H., Shiroya T., Kawaguchi H. Enhancement of sensitivity of SPR protein microarray using a novel 3D protein immobilization. Colloids Surf B Biointerfaces 2009, 70:259-265.
138. Chen H., Jiang C., Yu C., Zhang S., Liu B., Kong J. Protein chips and nanomaterials for application in tumor marker immunoassays. Biosens Bioelectron 2009, 24:3399-3411.
139. Tsarfati-Barad I., Sauer U., Preininger C., Gheber L.A. Miniaturized protein arrays: Model and experiment. Biosens Bioelectron 2011, 26:3774-3781.
140. Chandra H., Reddy P.J., Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011, 8:61-79.
141. Haab B.B., Dunham M.J., Brown P.O. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2001, 2. RESEARCH0004, [RESEARCH0004].
142. Sreekumar A., Nyati M.K., Varambally S., Barrette T.R., Ghosh D., Lawrence T.S., et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 2001, 61:7585-7593.
143. Schweitzer B., Roberts S., Grimwade B., Shao W., Wang M., Fu Q., et al. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol 2002, 20:359-365.
144. Nolen B.M., Marks J.R., Ta'san S., Rand A., Luong T.M., Wang Y., et al. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008, 10:R45.
145. Carlsson A., Wingren C., Kristensson M., Rose C., Fernö M., Olsson H., et al. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U S A 2011, 108:14252-14257.
146. Pla-Roca M., Leulmi R.F., Tourekhanova S., Bergeron S., Laforte V., Moreau E., et al. Antibody colocalization microarray: a scalable technology for multiplex protein analysis in complex samples. Mol Cell Proteomics 2011, 11. [M111.011460].
147. Bouwman K., Qiu J., Zhou H., Schotanus M., Mangold L.A., Vogt R., et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003, 3:2200-2207.
148. Yan F., Sreekumar A., Laxman B., Chinnaiyan A.M., Lubman D.M., Barder T.J. Protein microarrays using liquid phase fractionation of cell lysates. Proteomics 2003, 3:1228-1235.
149. Qiu J., Madoz-Gurpide J., Misek D.E., Kuick R., Brenner D.E., Michailidis G., et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004, 3:261-267.
150. Pereira-Faca S.R., Kuick R., Puravs E., Zhang Q., Krasnoselsky A.L., Phanstiel D., et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res Dec 2007, 67:12000-12006.
151. Madoz-Gurpide J., Kuick R., Wang H., Misek D.E., Hanash S.M. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 2008, 7:268-281.
152. Albala J.S., Franke K., McConnell I.R., Pak K.L., Folta P.A., Rubinfeld B., et al. From genes to proteins: high-throughput expression and purification of the human proteome. J Cell Biochem 2000, 80:187-191.
153. Hollister J., Grabenhorst E., Nimtz M., Conradt H., Jarvis D.L. Engineering the protein N-glycosylation pathway in insect cells for production of biantennary, complex N-glycans. Biochemistry 2002, 41:15093-15104.
154. Schena M. Protein microarrays 2005, Jones and Bartlett, Sudbury, Mass.
155. Sreekumar A., Laxman B., Rhodes D.R., Bhagavathula S., Harwood J., Giacherio D., et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004, 96:834-843.
156. Taylor B.S., Pal M., Yu J., Laxman B., Kalyana-Sundaram S., Zhao R., et al. Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2008, 7:600-611.
157. Anderson K.S., Sibani S., Wallstrom G., Qiu J., Mendoza E.A., Raphael J., et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011, 10:85-96.